The present study findings are consistent with Kamiya et al. (2019) study in breast cancer patients demonstrating that decreased parasympathetic nerve density, determined by vesicular acetylcholine transporter expression, was associated with poor clinical outcomes and elevated levels of immune checkpoint molecules [71]. The gene discussed is SLC18A3; the disease is breast cancer.